image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 0.9297
-10.3 %
$ 184 M
Market Cap
-3.04
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ESPR stock under the worst case scenario is HIDDEN Compared to the current market price of 0.93 USD, Esperion Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ESPR stock under the base case scenario is HIDDEN Compared to the current market price of 0.93 USD, Esperion Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ESPR stock under the best case scenario is HIDDEN Compared to the current market price of 0.93 USD, Esperion Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ESPR

image
$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.5Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
332 M REVENUE
185.66%
54.4 M OPERATING INCOME
134.97%
-51.7 M NET INCOME
75.27%
-23.7 M OPERATING CASH FLOW
82.54%
-317 K INVESTING CASH FLOW
-0.75%
86.5 M FINANCING CASH FLOW
71.39%
69.1 M REVENUE
33.86%
-4.42 M OPERATING INCOME
72.42%
-21.3 M NET INCOME
27.79%
-35 M OPERATING CASH FLOW
1.06%
0 INVESTING CASH FLOW
100.00%
35 M FINANCING CASH FLOW
484.78%
Balance Sheet Esperion Therapeutics, Inc.
image
Current Assets 338 M
Cash & Short-Term Investments 145 M
Receivables 80.1 M
Other Current Assets 113 M
Non-Current Assets 5.82 M
Long-Term Investments 0
PP&E 5.77 M
Other Non-Current Assets 56 K
42.10 %23.31 %32.89 %Total Assets$343.8m
Current Liabilities 246 M
Accounts Payable 51.6 M
Short-Term Debt 57.3 M
Other Current Liabilities 137 M
Non-Current Liabilities 486 M
Long-Term Debt 240 M
Other Non-Current Liabilities 246 M
7.05 %7.82 %18.74 %32.80 %33.58 %Total Liabilities$732.5m
EFFICIENCY
Earnings Waterfall Esperion Therapeutics, Inc.
image
Revenue 332 M
Cost Of Revenue 0
Gross Profit 332 M
Operating Expenses 278 M
Operating Income 54.4 M
Other Expenses 106 M
Net Income -51.7 M
350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)332m0332m(278m)54m(106m)(52m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
16.37% OPERATING MARGIN
16.37%
-15.57% NET MARGIN
-15.57%
13.31% ROE
13.31%
-15.05% ROA
-15.05%
35.12% ROIC
35.12%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Esperion Therapeutics, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -51.7 M
Depreciation & Amortization 63 K
Capital Expenditures -317 K
Stock-Based Compensation 12 M
Change in Working Capital 0
Others 16 M
Free Cash Flow -24 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Esperion Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for ESPR of $12 , with forecasts ranging from a low of $8 to a high of $20 .
ESPR Lowest Price Target Wall Street Target
8 USD 760.49%
ESPR Average Price Target Wall Street Target
12 USD 1190.74%
ESPR Highest Price Target Wall Street Target
20 USD 2051.23%
Price
Max Price Target
Min Price Target
Average Price Target
2020181816161414121210108866442200Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership Esperion Therapeutics, Inc.
image
Sold
0-3 MONTHS
29.1 K USD 3
3-6 MONTHS
44.7 K USD 3
6-9 MONTHS
31.4 K USD 2
9-12 MONTHS
19.8 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Esperion Therapeutics (ESPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. zacks.com - 1 week ago
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025 Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases globenewswire.com - 3 weeks ago
Esperion Appoints Robert E. Hoffman to Board of Directors - Veteran Industry Executive Brings Decades of Financial and Leadership Experience - ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Robert E. globenewswire.com - 1 month ago
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia. zacks.com - 1 month ago
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y Esperion reports a narrower-than-expected loss for the fourth quarter of 2024. Revenues lag estimates. zacks.com - 1 month ago
Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Chief Executive Officer Ben Halladay - Chief Financial Officer Eric Warren - Chief Commercial Officer Conference Call Participants Dennis Ding - Jefferies Joseph Pantginis - H.C. Wainwright Thomas Shrader - BTIG Tanmay Patwardhan - JPMorgan Jason Zemansky - Bank of America Serge Belanger - Needham Paul Choi - Goldman Sachs Kristen Kluska - Cantor Fitzgerald Operator Ladies and gentlemen, thank you for standing by, and welcome. seekingalpha.com - 1 month ago
Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.50 per share a year ago. zacks.com - 1 month ago
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results – FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million – globenewswire.com - 1 month ago
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia – Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales – – Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales – globenewswire.com - 2 months ago
Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 months ago
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4 ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025. globenewswire.com - 2 months ago
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on February 11, 2025, the Company granted ten new employees 58,300 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. globenewswire.com - 2 months ago
8. Profile Summary

Esperion Therapeutics, Inc. ESPR

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 184 M
Dividend Yield 0.00%
Description Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Contact 3891 Ranchero Drive, Ann Arbor, MI, 48108 https://www.esperion.com
IPO Date June 26, 2013
Employees 304
Officers Mr. Sheldon L. Koenig President, Chief Executive Officer & Director